ALX Oncology Holdings Statistics
Total Valuation
ALXO has a market cap or net worth of $23.26 million. The enterprise value is -$58.68 million.
Important Dates
The last earnings date was Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ALXO has 53.44 million shares outstanding. The number of shares has increased by 16.96% in one year.
| Current Share Class | 53.44M |
| Shares Outstanding | 53.44M |
| Shares Change (YoY) | +16.96% |
| Shares Change (QoQ) | +1.05% |
| Owned by Insiders (%) | 2.45% |
| Owned by Institutions (%) | 51.94% |
| Float | 32.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.26 |
| P/TBV Ratio | 0.26 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.47, with a Debt / Equity ratio of 0.19.
| Current Ratio | 5.47 |
| Quick Ratio | 5.27 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -79.93 |
Financial Efficiency
Return on equity (ROE) is -102.99% and return on invested capital (ROIC) is -59.69%.
| Return on Equity (ROE) | -102.99% |
| Return on Assets (ROA) | -51.16% |
| Return on Invested Capital (ROIC) | -59.69% |
| Return on Capital Employed (ROCE) | -133.64% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.63M |
| Employee Count | 80 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -97.32% in the last 52 weeks. The beta is 1.21, so ALXO's price volatility has been higher than the market average.
| Beta (5Y) | 1.21 |
| 52-Week Price Change | -97.32% |
| 50-Day Moving Average | 0.66 |
| 200-Day Moving Average | 1.56 |
| Relative Strength Index (RSI) | 33.45 |
| Average Volume (20 Days) | 512,667 |
Short Selling Information
The latest short interest is 6.05 million, so 11.32% of the outstanding shares have been sold short.
| Short Interest | 6.05M |
| Short Previous Month | 6.14M |
| Short % of Shares Out | 11.32% |
| Short % of Float | 18.69% |
| Short Ratio (days to cover) | 11.62 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -136.53M |
| Pretax Income | -166.20M |
| Net Income | -130.02M |
| EBITDA | -135.66M |
| EBIT | -136.53M |
| Earnings Per Share (EPS) | -$2.45 |
Full Income StatementBalance Sheet
The company has $97.83 million in cash and $16.59 million in debt, giving a net cash position of $81.25 million or $1.52 per share.
| Cash & Cash Equivalents | 97.83M |
| Total Debt | 16.59M |
| Net Cash | 81.25M |
| Net Cash Per Share | $1.52 |
| Equity (Book Value) | 88.30M |
| Book Value Per Share | 1.65 |
| Working Capital | 83.79M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$108.65 million and capital expenditures -$359,000, giving a free cash flow of -$109.01 million.
| Operating Cash Flow | -108.65M |
| Capital Expenditures | -359,000 |
| Free Cash Flow | -109.01M |
| FCF Per Share | -$2.04 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |